October 26, 2006 Multicell Technologies, Inc.Worldwide Exclusive License Agreement • November 1st, 2006 • MultiCell Technologies, Inc. • Surgical & medical instruments & apparatus
October 26, 2006Worldwide Exclusive License Agreement • March 5th, 2007 • Amarin Corp Plc\uk • Pharmaceutical preparations
WORLDWIDE EXCLUSIVE LICENSE AGREEMENTWorldwide Exclusive License Agreement • January 11th, 2021 • Omnia Wellness Inc. • Services-prepackaged software • Colorado
THIS LICENSE AGREEMENT (hereinafter “Agreement”), effective as of April 30, 2019 (the “Effective Date”), is entered into between Drywave Technologies USA, Inc., a Delaware corporation (“DWTI”), having a place of business in Denver, Colorado, and Bed Therapies, LLC a Texas Limited Liability Company (“BT”), having a place of business in Dallas, Texas.
WORLDWIDE EXCLUSIVE LICENSE AGREEMENT by and between EVOLUTION BIOTECHNOLOGIES LIMITED and AERIS BIOTECHNOLOGIES INC.Worldwide Exclusive License Agreement • April 25th, 2022 • Aeris Biotechnologies, Inc. • Delaware
June 27th 2006 Multicell Technologies, Inc.Worldwide Exclusive License Agreement • July 5th, 2006 • MultiCell Technologies, Inc. • Surgical & medical instruments & apparatus
WORLDWIDE EXCLUSIVE LICENSE AGREEMENTWorldwide Exclusive License Agreement • January 12th, 2006 • MultiCell Technologies, Inc. • Surgical & medical instruments & apparatus • Delaware
This License Agreement (the "Agreement") is made and entered into as of December 31, 2005 ("Effective Date") by and between Amarin Neuroscience Limited, a company organized under the laws of Scotland whose principal place of business is at Kings Park House, Laurehill Business Park, Polmaise Road, Stirling FK7 9JQ, Scotland, UK ("Amarin"), and Multicell Technologies, Inc., a corporation organized under the laws of the State of Delaware whose principal place of business is at 701 George Washington Highway, Lincoln, RI 02865 ("Multicell"). Amarin and Multicell are sometimes each hereinafter referred to as a "Party" or collectively as "Parties" to this Agreement.
First Amendment to Worldwide Exclusive License AgreementWorldwide Exclusive License Agreement • June 7th, 2022 • Aeris Biotechnologies, Inc. • Pharmaceutical preparations
THIS FIRST AMENDMENT TO WORLDWIDE EXCLUSIVE LICENSE AGREEMENT (“Amendment”) is executed and effective this 22nd day of May, 2022 by and between Aeris Biotechnologies, Inc. (“Aeris”) and Evolution Biotechnologies, Limited (“Evolution”).
